Suzanne M. Hanlon's most recent trade in Zynerba Pharmaceuticals Inc was a trade of 55,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 21, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zynerba Pharmaceuticals Inc | Suzanne M. Hanlon | Sec, VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Zynerba Pharmaceuticals Inc | Suzanne M. Hanlon | Sec, VP & General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 37,000 | 80,693 (0%) | 0% | 0 | Common Stock |